Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2023 Earnings Conference Call November 6, 2023 8:00 AM ET
Company Participants
Mark Jacobson - Chief Operating Officer
Herriot Tabuteau - Chief Executive Officer
Nick Pizzie - Chief Financial Officer
Lori Englebert - Executive Vice President, Commercial and Business Development
Hunter Murdock - General Counsel
Conference Call Participants
Charles Duncan - Cantor Fitzgerald
Rudy Li - Leerink Partners
Vikram Purohit - Morgan Stanley
David Amsellem - Piper Sandler
Jason Gerberry - Bank of America
Joon Lee - Truist Securities
Raghuram Selvaraju - H.C. Wainwright
Joseph Thome - TD Cowen
Eddie Hickman - Guggenheim
Graig Suvannavejh - Mizuho Securities
Matt Kaplan - Ladenburg Thalmann
Operator
Good morning and welcome to Axsome Therapeutics Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Later, there will be a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, today's conference is being recorded.
I would now like to turn the conference over to your host Mark Jacobson, Chief Operating Officer at Axsome Therapeutics. Thank you. Please go ahead.
Mark Jacobson
Good morning and thank you all for joining us on today's conference call. This morning we issued our earnings press release, providing corporate update and details of the company's financial results for the third quarter of 2023. The release crossed the wire a short time ago is available on our website at axsome.com.
During today's call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our investigational agents, our clinical and nonclinical plans, our plans to present or report additional data, the anticipated conduct and the source of future clinical trials, regulatory plan, future research and development plan, our commercial plans regarding Sunosi, Auvelity, and our other pipeline products, revenue projections and possible intended use of cash and investments.
These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements.
These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our quarterly and annual report. You are cautioned not to place undue reliance on these forward-looking statements, which are only made as of today's date and the company disclaims any obligation to update such statements.